Danon Disease: Understanding the Role of LAMP2 Variants in Cardiomyopathy and Multisystemic Involvement.
Authors:
- Giovanna Napolitano Pereira RibeiroGRGiovanna Napolitano Pereira Ribeiro
- Layara Fernanda Vicente Pereira LipariLLLayara Fernanda Vicente Pereira Lipari
- Lucas Vieira Lacerda PiresLPLucas Vieira Lacerda Pires
- Marjorie Hayashida MizutaMMMarjorie Hayashida Mizuta
- Natália Quintella Sangiorgi OlivettiNONatália Quintella Sangiorgi Olivetti
Open Access
- 15 May 2026
- journal article
- review article
- Vol. 123 (3) , e20250186
Abstract
Danon disease (DD) is a rare X-linked disorder caused by pathogenic or likely pathogenic variants in the lysosome-associated membrane protein 2 (LAMP2) gene. It primarily manifests as hypertrophic cardiomyopathy, myopathy, intellectual disability, and retinopathy, with males typically experiencing a more severe and early-onset phenotype. The pathophysiology of DD is linked to defective autophagy due to LAMP2 deficiency, leading to the accumulation of glycogen-filled vacuoles within cardiomyocytes and other tissues. This results in progressive cardiac hypertrophy, conduction abnormalities, and eventual heart failure, often necessitating heart transplantation. Skeletal muscle involvement is common in males, while cognitive impairments are observed in both genders, though more prevalent in males. Diagnosis is challenging due to the condition's rarity and variable presentation, highlighting the need for a multidisciplinary approach, including genetic testing for definitive diagnosis. Genetic testing must be performed only after proper genetic counseling is done. Differential diagnosis must be considered when DD is suspected, depending on the signs and symptoms, such as Fabry disease, PRKAG2, Pompe disease, and others. Management strategies currently focus on symptomatic treatment, with cardiac transplantation as a critical intervention for advanced cases. Emerging therapies, such as gene therapy targeting LAMP2, could help in altering disease progression. This review provides a comprehensive overview of DD, discussing its clinical manifestations, underlying mechanisms, diagnostic challenges, and potential therapeutic approaches in improving outcomes. Our goal is to increase the recognition of DD so that the prevention of possible complications and early diagnosis becomes feasible, ultimately leading to more favorable patient outcomes.Keywords
This publication has 45 references indexed in Scilit:
- Unifying Nomenclature for the Isoforms of the Lysosomal Membrane Protein LAMP‐2Traffic, 2005
- Glycogen Storage Diseases Presenting as Hypertrophic CardiomyopathyNew England Journal of Medicine, 2005
- Danon’s disease as a cause of hypertrophic cardiomyopathy: a systematic surveyHeart, 2004
- Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease)Nature, 2000
- A Receptor for the Selective Uptake and Degradation of Proteins by LysosomesScience, 1996
- An Alternatively Spliced Form of the Human Lysosome-Associated Membrane Protein-2 Gene Is Expressed in a Tissue-Specific MannerBiochemical and Biophysical Research Communications, 1995
- The Family of LAMP-2 Proteins Arises by Alternative Splicing from a Single Gene: Characterization of the Avian LAMP-2 Gene and Identification of Mammalian Homologs of LAMP-2b and LAMP-2cDNA and Cell Biology, 1995
- Multiple mRNAs encode the avian lysosomal membrane protein LAMP-2, resulting in alternative transmembrane and cytoplasmic domainsJournal of Cell Science, 1995
- Confirmation of the chromosomal localization of human lamp genes and their exclusion as candidate genes for Salla diseaseHuman Genetics, 1991
- Lysosomal glycogen storage disease without acid maltase deficiencyNeurology, 1983